Literature DB >> 21146547

Inhibition of semicarbazide-sensitive amine oxidase attenuates myocardial ischemia-reperfusion injury in an in vivo rat model.

Wei Yang1, Hui Li, Hongjun Luo, Wenhong Luo.   

Abstract

AIMS: This study tested the hypothesis that the inhibition of semicarbazide-sensitive amine oxidase (SSAO) after ischemia could attenuate myocardial ischemia-reperfusion (I/R) injury. MAIN
METHODS: Anesthetized male Sprague-Dawley rats underwent myocardial I/R injury. Saline, semicarbazide (SCZ, 30 mg/kg), hydralazine (HYD, 10mg/kg), or LJP 1207 (30 mg/kg) was administered intraperitoneally 3 min before reperfusion. After 30 min of ischemia and 180 min of reperfusion, the myocardial infarct size was determined using nitroblue tetrazolium staining. Myocardial myeloperoxidase activity was determined through biochemical assay. HE staining was used for histopathological evaluation. Myocardial SSAO activity was assayed with high performance liquid chromatography analysis. Additionally, the endothelial expression of P-selectin was evaluated using immunohistochemistry after 30 min of ischemia and 20 min of reperfusion. KEY
FINDINGS: Myocardial SSAO activity was increased in myocardial I/R injury. Administration of SCZ, HYD, or LJP 1207 reduced the myocardial infarct size and decreased leukocyte infiltration and endothelial P-selectin expression in myocardial I/R injury in vivo. SIGNIFICANCE: These data suggest that myocardial I/R injury up-regulates myocardial SSAO activity, and the inhibition of SSAO prior to reperfusion is able to attenuate acute myocardial I/R injury.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21146547     DOI: 10.1016/j.lfs.2010.12.003

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  6 in total

1.  Lack of association between VAP-1/SSAO activity and corneal neovascularization in a rabbit model.

Authors:  Anna Énzsöly; Katalin Markó; Tamás Tábi; Éva Szökő; Romána Zelkó; Miklós Tóth; J Mark Petrash; Péter Mátyus; János Németh
Journal:  J Neural Transm (Vienna)       Date:  2013-02-09       Impact factor: 3.575

Review 2.  Human Copper-Containing Amine Oxidases in Drug Design and Development.

Authors:  Serhii Vakal; Sirpa Jalkanen; Käthe M Dahlström; Tiina A Salminen
Journal:  Molecules       Date:  2020-03-12       Impact factor: 4.411

Review 3.  Vascular Adhesion Protein-1: A Cell Surface Amine Oxidase in Translation.

Authors:  Marko Salmi; Sirpa Jalkanen
Journal:  Antioxid Redox Signal       Date:  2017-12-07       Impact factor: 8.401

Review 4.  SSAO/VAP-1 in Cerebrovascular Disorders: A Potential Therapeutic Target for Stroke and Alzheimer's Disease.

Authors:  Mercedes Unzeta; Mar Hernàndez-Guillamon; Ping Sun; Montse Solé
Journal:  Int J Mol Sci       Date:  2021-03-25       Impact factor: 5.923

Review 5.  Vascular Adhesion Protein-1 (VAP-1)/Semicarbazide-Sensitive Amine Oxidase (SSAO): A Potential Therapeutic Target for Atherosclerotic Cardiovascular Diseases.

Authors:  Hui Li; Shiyu Du; Panpan Niu; Xiaosong Gu; Jun Wang; Ying Zhao
Journal:  Front Pharmacol       Date:  2021-07-08       Impact factor: 5.810

6.  Hydralazine protects the heart against acute ischaemia/reperfusion injury by inhibiting Drp1-mediated mitochondrial fission.

Authors:  Siavash Beikoghli Kalkhoran; Janos Kriston-Vizi; Sauri Hernandez-Resendiz; Gustavo E Crespo-Avilan; Ayeshah A Rosdah; Jarmon G Lees; Joana Rodrigues Simoes Da Costa; Naomi X Y Ling; Jessica K Holien; Parisa Samangouei; Kroekkiat Chinda; En Ping Yap; Jaime A Riquelme; Robin Ketteler; Derek M Yellon; Shiang Y Lim; Derek J Hausenloy
Journal:  Cardiovasc Res       Date:  2022-01-07       Impact factor: 10.787

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.